CoChat

Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022

Open access
Fowlkes, Ashley L., Yoon, Sarang K., Lutrick, Karen, Gwynn, Lisa, Burns, Joy, Grant, Lauren, Phillips, Andrew L., Ellingson, Katherine, Ferraris, Maria V., LeClair, Lindsay B., Mathenge, Clare, Yoo, Young M., Thiese, Matthew S., Gerald, Lynn B., Solle, Natasha Schaefer, Jeddy, Zuha, Odame-Bamfo, Leah, Mak, Josephine, Hegmann, Kurt T., Gerald, Joe K., Ochoa, Jezahel S., Berry, Mark, Rose, Spencer, Lamberte, Julie Mayo, Madhivanan, Purnima, Pubillones, Felipe A., Rai, Ramona P., Dunnigan, Kayan, Jones, John T., Krupp, Karl, Edwards, Laura J., Bedrick, Edward J., Sokol, Brian E., Lowe, Ashley, McLeland-Wieser, Hilary, Jovel, Krystal S., Fleary, Deanna E., Khan, Sana M., Poe, Brandon, Hollister, James, Lopez, Joanna, Rivers, Patrick, Beitel, Shawn, Tyner, Harmony L., Naleway, Allison L., Olsho, Lauren E.W., Caban-Martinez, Alberto J., Burgess, Jefferey L., Thompson, Mark G., Gaglani, Manjusha · 2022 · MMWR. Morbidity and Mortality Weekly Report
Cited by 173

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

prospective cohort of 1,364 children and adolescents aged 5-15 years was tested weekly for SARS-CoV-2, irrespective of symptoms, and upon COVID-19-associated illness during July 25, 2021-February 12, 2022. Among unvaccinated participants (i.e., those who had received no COVID-19 vaccine doses) with any laboratory-confirmed SARS-CoV-2 infection, those with B.1.617.2 (Delta) variant infections were more likely to report COVID-19 symptoms (66%) than were those with Omicron infections (49%). Among fully vaccinated children aged 5-11 years, VE against any symptomatic and asymptomatic Omicron infection 14-82 days (the longest interval after dose 2 in this age group) after receipt of dose 2 of the Pfizer-BioNTech vaccine was 31% (95% CI = 9%-48%), adjusted for sociodemographic characteristics, health information, frequency of social contact, mask use, location, and local virus circulation. Among adolescents aged 12-15 years, adjusted VE 14-149 days after dose 2 was 87% (95% CI = 49%-97%) against symptomatic and asymptomatic Delta infection and 59% (95% CI = 22%-79%) against Omicron infection. Fully vaccinated participants with Omicron infection spent an average of one half day less sick in bed than did unvaccinated participants with Omicron infection. All eligible children and adolescents should remain up to date with recommended COVID-19 vaccinations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15585/mmwr.mm7111e1

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 173

Metadata

Authors
Fowlkes, A. L., Yoon, S. K., Lutrick, K., Gwynn, L., Burns, J., Grant, L., Phillips, A. L., Ellingson, K., Ferraris, M. V., LeClair, L. B., Mathenge, C., Yoo, Y. M., Thiese, M. S., Gerald, L. B., Solle, N. S., Jeddy, Z., Odame-Bamfo, L., Mak, J., Hegmann, K. T., Gerald, J. K., Ochoa, J. S., Berry, M., Rose, S., Lamberte, J. M., Madhivanan, P., Pubillones, F. A., Rai, R. P., Dunnigan, K., Jones, J. T., Krupp, K., Edwards, L. J., Bedrick, E. J., Sokol, B. E., Lowe, A., McLeland-Wieser, H., Jovel, K. S., Fleary, D. E., Khan, S. M., Poe, B., Hollister, J., Lopez, J., Rivers, P., Beitel, S., Tyner, H. L., Naleway, A. L., Olsho, L. E. W., Caban-Martinez, A. J., Burgess, J. L., Thompson, M. G., & Gaglani, M.
Venue
MMWR. Morbidity and Mortality Weekly Report
Published
2022-03-18
Volume
71
Issue
11
Pages
422-428
ISSN
  • 0149-2195 (ISSN-L)
  • 1545-861X
OpenAlex
W4220692166
Cited by
173
References
4
FWCI
19.17
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.